Related Experiment Videos
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) produces edema due to BBB disruption induced by MMP-9 activation in
Mercedes Pérez-Hernández1, María Encarnación Fernández-Valle2, Ana Rubio-Araiz1
1Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Pza. Ramón y Cajal s/n, 28040 Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre, 28041 Madrid, Spain; Red de Trastornos Adictivos del Instituto de Salud Carlos III, 28029 Madrid, Spain.
Abstract:
The recreational drug of abuse, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) disrupts blood-brain barrier (BBB) integrity in rats through an early P2X7 receptor-mediated event which induces MMP-9 activity. Increased BBB permeability often causes plasma proteins and water to access cerebral tissue leading to vasogenic edema formation. The current study was performed to examine the effect of a single neurotoxic dose of MDMA (12.5 mg/kg, i.p.) on in vivo edema development associated with changes in the expression of the perivascular astrocytic water channel, AQP4, as well as in the expression of the tight-junction (TJ) protein, claudin-5 and Evans Blue dye extravasation in the hippocampus of adult male Dark Agouti rats. We also evaluated the ability of the MMP-9 inhibitor, SB-3CT (25 mg/kg, i.p.), to prevent these changes in order to validate the involvement of MMP-9 activation in MDMA-induced BBB disruption. The results show that MDMA produces edema of short duration temporally associated with changes in AQP4 expression and a reduction in claudin-5 expression, changes which are prevented by SB-3CT. In addition, MDMA induces a short-term increase in both tPA activity and expression, a serine-protease which is involved in BBB disruption and upregulation of MMP-9 expression. In conclusion, this study provides evidence enough to conclude that MDMA induces edema of short duration due to BBB disruption mediated by MMP-9 activation.
Insights
3,4-methylenedioxymethamphetamine (MDMA) disrupts the blood-brain barrier (BBB) in rats, causing temporary brain edema. This effect is mediated by MMP-9 activation and can be prevented by an MMP-9 inhibitor.
Area of Science:
- Neuroscience
- Pharmacology
- Toxicology
Background:
- Recreational drug 3,4-methylenedioxymethamphetamine (MDMA) disrupts blood-brain barrier (BBB) integrity.
- MDMA-induced BBB disruption is linked to P2X7 receptor activation and matrix metalloproteinase-9 (MMP-9) activity.
- Increased BBB permeability can lead to vasogenic edema formation in cerebral tissue.
Purpose of the Study:
- To investigate the effects of a single neurotoxic MDMA dose on in vivo edema development in the rat hippocampus.
- To examine MDMA's impact on aquaporin-4 (AQP4) and claudin-5 expression and Evans Blue dye extravasation.
- To evaluate the efficacy of an MMP-9 inhibitor (SB-3CT) in preventing MDMA-induced BBB changes.
Main Methods:
- Administration of a single neurotoxic dose of MDMA (12.5 mg/kg, i.p.) to adult male Dark Agouti rats.
- Assessment of in vivo edema, AQP4 and claudin-5 expression, and Evans Blue extravasation in the hippocampus.
- Treatment with the MMP-9 inhibitor SB-3CT (25 mg/kg, i.p.) to assess its preventative effects.
Main Results:
- MDMA induced a short-duration edema associated with changes in AQP4 expression and reduced claudin-5 expression.
- These MDMA-induced changes were prevented by the MMP-9 inhibitor SB-3CT.
- MDMA also caused a transient increase in tPA activity and expression, contributing to BBB disruption and MMP-9 upregulation.
Conclusions:
- MDMA induces short-term brain edema primarily through MMP-9 activation, leading to blood-brain barrier disruption.
- The study validates the critical role of MMP-9 in MDMA-induced BBB damage.
- Targeting MMP-9 may offer a therapeutic strategy against MDMA-induced neurotoxicity.